Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets

Por Othman, Ahmed A, Dutta, Sandeep
Publicado em 2014

The Novel N-Substituted Benztropine Analog GA2-50 Possesses Pharmacokinetic and Pharmacodynamic Profiles Favorable for a Candidate Substitute Medication for Cocaine Abuse

Por OTHMAN, AHMED A., NEWMAN, AMY H., EDDINGTON, NATALIE D.
Publicado em 2008

The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study

Por Haig, George, Wang, Deli, Othman, Ahmed A, Zhao, Jun
Publicado no Neuropsychopharmacology (2016)

Effects of the TRPV1 antagonist ABT-102 on body temperature in healthy volunteers: pharmacokinetic/pharmacodynamic analysis of three phase 1 trials

Por Othman, Ahmed A, Nothaft, Wolfram, Awni, Walid M, Dutta, Sandeep
Publicado em 2013

Therapeutic protein–drug interaction assessment for daclizumab high‐yield process in patients with multiple sclerosis using a cocktail approach

Por Tran, Jonathan Q., Othman, Ahmed A., Wolstencroft, Paul, Elkins, Jacob
Publicado no Br J Clin Pharmacol (2016)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa

Por Othman, Ahmed A., Rosebraugh, Matthew, Chatamra, Krai, Locke, Charles, Dutta, Sandeep
Publicado no J Parkinsons Dis (2017)

Pharmacokinetics of daclizumab high-yield process with repeated administration of the clinical subcutaneous regimen in patients with relapsing-remitting multiple sclerosis

Por Tran, Jonathan Q, Othman, Ahmed A, Mikulskis, Alvydas, Wolstencroft, Paul, Elkins, Jacob
Publicado no Clin Pharmacol (2016)

Safety, tolerability and pharmacokinetics of the histamine H(3) receptor antagonist, ABT-288, in healthy young adults and elderly volunteers

Por Othman, Ahmed A, Haig, George, Florian, Hana, Locke, Charles, Zhang, Jun, Dutta, Sandeep
Publicado em 2013

The H(3) antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers

Por Othman, Ahmed A, Haig, George, Florian, Hana, Locke, Charles, Gertsik, Lev, Dutta, Sandeep
Publicado em 2014

Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high‐fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib

Por Mohamed, Mohamed‐Eslam F., Jungerwirth, Steven, Asatryan, Armen, Jiang, Ping, Othman, Ahmed A.
Publicado no Br J Clin Pharmacol (2017)

Population pharmacokinetics of S(−)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the race...

Por Othman, Ahmed A., Tenero, David M., Boyle, Duane A., Eddington, Natalie D., Fossler, Michael J.
Publicado em 2007

Corrigendum: Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage form...

Por Othman, Ahmed A., Tenero, David M., Boyle, Duane A., Eddington, Natalie D., Fossler, Michael J.
Publicado em 2007

Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease Patients

Por Nyholm, Dag, Odin, Per, Johansson, Anders, Chatamra, Krai, Locke, Charles, Dutta, Sandeep, Othman, Ahmed A.
Publicado em 2012

A Randomized Trial of the Efficacy and Safety of the H3 Antagonist ABT-288 in Cognitive Impairment Associated With Schizophrenia

Por Haig, George M., Bain, Earle, Robieson, Weining, Othman, Ahmed A., Baker, Jeffrey, Lenz, Robert A.
Publicado em 2014

Population PK–PD analyses of CD25 occupancy, CD56(bright) NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis

Por Diao, Lei, Hang, Yaming, Othman, Ahmed A., Mehta, Devangi, Amaravadi, Lakshmi, Nestorov, Ivan, Tran, Jonathan Q.
Publicado no Br J Clin Pharmacol (2016)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinet...

Por Othman, Ahmed A., Chatamra, Krai, Mohamed, Mohamed-Eslam F., Dutta, Sandeep, Benesh, Janet, Yanagawa, Masayoshi, Nagai, Masahiro
Publicado no Clin Pharmacokinet (2015)

Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia

Por Bain, Earle E, Shafner, Laura, Walling, David P, Othman, Ahmed A, Chuang-Stein, Christy, Hinkle, John, Hanina, Adam
Publicado no JMIR Mhealth Uhealth (2017)

An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UV(B)-inflamed and normal skin

Por Schaffler, Klaus, Reeh, Peter, Duan, W Rachel, Best, Andrea E, Othman, Ahmed A, Faltynek, Connie R, Locke, Charles, Nothaft, Wolfram
Publicado em 2013

Azithromycin To Prevent Bronchopulmonary Dysplasia in Ureaplasma-Infected Preterm Infants: Pharmacokinetics, Safety, Microbial Response, and Clinical Outcomes with a 20-Milligram-p...

Por Viscardi, Rose M., Othman, Ahmed A., Hassan, Hazem E., Eddington, Natalie D., Abebe, Elias, Terrin, Michael L., Kaufman, David A., Waites, Ken B.
Publicado em 2013

ABT-126 monotherapy in mild-to-moderate Alzheimer’s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension

Por Gault, Laura M., Lenz, Robert A., Ritchie, Craig W., Meier, Andreas, Othman, Ahmed A., Tang, Qi, Berry, Scott, Pritchett, Yili, Robieson, Weining Z.
Publicado no Alzheimers Res Ther (2016)